Effect of Nano-curcumin in Coronary Slow Flow Phenomeno

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 42

Inclusion Criteria

35 to 70 years old men and women
BMI range: 25 - 39.9
Angiographically diagnosed as coronary slow flow phenomenon by Corrected TIMI Frame Count (CTFC) method which is equivalent to 27 or higher for one or more coronary vessels.
Normal coronary vessels with coronary stenosis less than 40%
Left ventricular ejection fraction higher than 45%
Giving informed consent for participation in the study

Exclusion Criteria

Premature menopause
addiction or alcohol consumption
Routine use of NSAIDs or antioxidants one month prior to study
Use of aphrodisiac medication within 9 months before study
Routine use of corticosteroids or immunosuppressants
Use of anticonvulsants
Taking antioxidant or omega3 supplements (more than 3 grams per day) at least twice a week within 3 months prior to study
Taking vitamin B12, folic acid or vitamin B6 supplements within one month before study
Being a professional athlete or execising regularly
Uncontrolled hypertension defined as diastolic blood pressure above 90 mmHg, systolic blood pressure above 140 mmHg.
Past medical history: hypothyroidism or hyperthyroidism
Malignancy
Chronic obstructive pulmonary diseases
Systemic diseases
Connective tissue diseases
Renal failure
Liver failure
Autoimmune diseases
Myocardial Infarction
Sever heart failure
Heart transplant
Revascularization procedure or PCI or CABG
Left ventricular dysfunction or echocardiographically diagnosed left ventricular hypertrophy
Cardiac conduction disturbances
Valvular heart disease
Atrial fibrillation
Aneurysms
Cardiomyopathy
Congenital heart disease
Coronary artery disease
Hematologic disorders

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Homocysteine levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic Kit.;Serum Adropin levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum Endocan levels. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Different aspects of angina pectoris. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Seattle Angina Questionnore.;Serum visfatin level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum hs-CRP level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA kit.;Serum uric acid level. Timepoint: Before and after 12 weeks of intervention. Method of measurement: enzymatic kit.;Quality of life. Timepoint: Before and after 12 weeks of intervention. Method of measurement: SF-36 items questionnaire.

Secondary Outcome Measures